Literature DB >> 17523319

Hepatitis B today.

Michael Safioleas1, Nikolaos J Lygidakis, Christine Manti.   

Abstract

Hepatitis B remains a major problem for public health worldwide and represents a challenging disease for practicing physicians. Of the 2 billion people who have been infected with the hepatitis B virus, more than 350 million have chronic infections. These chronically infected individuals are at high risk of death from cirrhosis and liver cancer. The use of new antiviral drugs, such us nucleotides analogues, offer good hope in the prognosis of patients suffering from chronic hepatitis B.

Entities:  

Mesh:

Year:  2007        PMID: 17523319

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.

Authors:  Weixia Ke; Chi Zhang; Li Liu; Yanhui Gao; Zhenjiang Yao; Xiaohua Ye; Shudong Zhou; Yi Yang
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

Review 2.  Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.

Authors:  Shushan Zhao; Lanhua Tang; Xuegong Fan; Lizhang Chen; Rongrong Zhou; Xiahong Dai
Journal:  Virol J       Date:  2010-09-03       Impact factor: 4.099

Review 3.  Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis.

Authors:  H Jiang; J Wang; W Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-17       Impact factor: 3.267

4.  A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China.

Authors:  Tao-Tao Liu; Ying Fang; Hui Xiong; Tao-Yang Chen; Zheng-Pin Ni; Jian-Feng Luo; Nai-Qing Zhao; Xi-Zhong Shen
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 5.  Natural products as promising drug candidates for the treatment of hepatitis B and C.

Authors:  Carolin Wohlfarth; Thomas Efferth
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

Review 6.  Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis.

Authors:  Qin-Qin Zhang; Xuan An; Ying-Hong Liu; Shi-Ying Li; Qing Zhong; Jing Wang; Huai-Dong Hu; Da-Zhi Zhang; Hong Ren; Peng Hu
Journal:  Virol J       Date:  2011-02-15       Impact factor: 4.099

Review 7.  Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.

Authors:  Shu-Shan Zhao; Lan-Hua Tang; Xia-Hong Dai; Wei Wang; Rong-Rong Zhou; Li-Zhang Chen; Xue-Gong Fan
Journal:  Virol J       Date:  2011-03-09       Impact factor: 4.099

Review 8.  Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.

Authors:  Weixia Ke; Li Liu; Chi Zhang; Xiaohua Ye; Yanhui Gao; Shudong Zhou; Yi Yang
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.

Authors:  Qiao-Ling Xie; Ying Zhu; Ling-Hong Wu; Lin-Lin Fu; Yan Xiang
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

10.  Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.

Authors:  Hong Shi; Mingxing Huang; Guoli Lin; Xiangyong Li; Yuankai Wu; Yusheng Jie; Yutian Chong
Journal:  Biomed Res Int       Date:  2016-03-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.